PsychoactiveMap

Psychedelic and ketamine research trials in Pakistan

Curated snapshot as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap.

This is a dated selection from the broader clinical catalogue for Pakistan, not a complete inventory of research. The catalogue loads separately, may show cached records, and includes compounds and ketamine uses outside this hub's scope. Scope and update timing can produce different totals. Historical publications are separate from these registered-study counts.

3 registered studies are counted in Pakistan. By compound: 2 psilocybin and 1 ketamine. By registry status: 1 recruiting and 2 completed. By phase: 1 phase 2, 1 phase 3 and 1 not applicable. Reported start years run from 2024 (earliest) to 2026 (latest). Studies are linked to 5 source-listed facility records.

Country is taken from the research sites linked to each registry record. A study counts once per country and may appear in several countries. Compound counts may overlap. This directory covers its linked compound hubs; the research map and MCP connector also include other compounds. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.

Facility records may include aliases or departments of the same institution; they are not a count of unique institutions. A listed facility does not establish a sponsor, lead site or care provider role, or confirm recruitment.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

Recruiting or not yet recruiting

1 of the 3 counted studies is listed in the registry as recruiting (1) or not yet recruiting (0), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.

Title as registeredRegistry IDStatusPhaseRegistry datesSource-listed facility and city
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive DisorderNCT07703722RecruitingPhase 3Source start: 2026-04-01 (actual)
Source date details

Start: 2026-04-01 (precision: day; source type: ACTUAL; actual)

Primary completion: 2027-10-22 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2027-11-22 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.880Z; registry revision: 2026-07-14 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Khyber Medical University, Peshawar; Institute of Health Science, Khyber Medical University, Islamabad; Hayatabad Medical Complex Peshawar, Peshawar

At a glance

By compound

Compound hubStudies
Psilocybin2
Ketamine1

By registry status

StatusStudiesShare
Recruiting133%
Completed267%

By phase

PhaseStudiesShare
Phase 2133%
Phase 3133%
Not applicable133%

Registry-listed start years

Start yearStudies
2024 and later3

All counted studies

All 3 counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registeredRegistry IDStatusPhaseRegistry datesSource-listed facility and city
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive DisorderNCT07703722RecruitingPhase 3Source start: 2026-04-01 (actual)
Source date details

Start: 2026-04-01 (precision: day; source type: ACTUAL; actual)

Primary completion: 2027-10-22 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2027-11-22 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.880Z; registry revision: 2026-07-14 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Khyber Medical University, Peshawar; Institute of Health Science, Khyber Medical University, Islamabad; Hayatabad Medical Complex Peshawar, Peshawar
Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive TherapyNCT07273851CompletedNot applicableSource start: 2025-07-01 (actual)
Source date details

Start: 2025-07-01 (precision: day; source type: ACTUAL; actual)

Primary completion: 2025-12-10 (precision: day; source type: ACTUAL; actual)

Study completion: 2025-12-10 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:18.483Z; registry revision: 2025-12-12 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Department of Anesthesia, Fauji Foundation Hospital, Rawalpindi, Pakistan, Rawalpindi
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity MarkersNCT06746441CompletedPhase 2Source start: 2024-12-01 (actual)
Source date details

Start: 2024-12-01 (precision: day; source type: ACTUAL; actual)

Primary completion: 2025-06-01 (precision: day; source type: ACTUAL; actual)

Study completion: 2025-07-30 (precision: day; source type: ACTUAL; actual)

Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2025-09-02 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Lady Reading Hospital, Pakistan, Peshawar

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Psilocybin | Ketamine

Condition hubs

Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.

Condition hubStudies in this country
Depression2
Post-traumatic stress disorder1

Other country hubs

United States | Canada | Switzerland | United Kingdom | Israel | Brazil | France | China | Netherlands | Germany | Spain | Austria | Australia | Poland | Czech Republic | Ireland | Denmark | Sweden | Taiwan | Argentina | Belgium | Finland | Turkey | Greece | Hungary | Italy | Mexico | Bulgaria | Egypt | Norway | Portugal

All trial hubs | Learn | Disclaimer